• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, March 13 A US District Court has granted a summary judgment that pharma major Dr Reddy’s Laboratories Ltd does not infringe the patents in its Abbreviated New Drug Application (ANDA) for Omeprazole.

The Hyderabad-based company got this favourable ruling in a litigation suit related to Astra Zeneca’s Prilosec.

Commenting on the judgment, Mr Amit Patel, Head, North America Generics, Dr Reddy’s, said: “We are very pleased with the favourable summary judgment ruling in the Omeprazole litigation. This is a key event supporting our strategy to deliver one upside opportunity every year.”

The company had submitted its ANDA filing and is awaiting response from the US Food and Drug Administration.

“We will continue to work through the regulatory approval process while simultaneously progressing manufacturing and commercialisation preparation (of the drug),” he added.

Omeprazole Mg is indicated for the treatment of heartburn.

More Stories on : IPR | Pharmaceuticals | Courts/Legal Issues | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line